Business
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium
SAN JOSE, Calif., Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the inventor of its ovarian cancer CAR-T technology, Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 15th Biennial Ovarian Cancer Research Symposium. Dr. Conejo-Garcia will be giving the opening keynote address on Friday, September 20, 2024.\n\n \n \n \n \n \n \n\n \nDuring the keynote address, Dr. Conejo-Garcia will discuss Anixa's chimeric antigen receptor-T cell (CAR-T) technology, which is an autologous cell therapy comprised of engineered T cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor-T cell) therapy, a new type of CAR-T. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute. Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical trial of this technology.\n\"I am pleased to discuss this novel FSHR-mediated CAR-T technology at the Ovarian Cancer Research Symposium and to share ideas and advance the field of ovarian cancer research,\" stated Dr. Conejo-Garcia. \"Anixa and its development partner, Moffitt Cancer Center, have been working together to advance this ovarian cancer therapy and we are excited about the clinical results to date—with the treatment appearing to be safe and well-tolerated, and some patients exhibiting tumor necrosis. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer.\"\nMore information about the event may be found at: https://rivkin.org/symposia/ocrs/.\nAbout Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed...